Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astrana HealthASTH +1.10%81 Days Sales Outstanding is 39.80 as of Mar. 2026, which is 203% above its 10-year median of 13.13. GuruFocus rates ASTH with a GF Score™ of 81/100 and a GF Value™ of $83.89 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 655 Healthcare Providers & Services companies, Astrana Health ranks better than 60.15% on this metric.
Astrana Health's average Accounts Receivable for the
three
months ended in Mar. 2026 was $421 Mil. Astrana Health's Revenue for the
three
months ended in Mar. 2026 was $965 Mil.
Hence, Astrana Health's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 39.80.
The historical rank and industry rank for Astrana Health's Days Sales Outstanding or its related term are showing as below:
ASTH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.17 Med: 13.13 Max: 37.53
Current: 37.53
During the past 13 years, Astrana Health's highest Days Sales Outstanding was 37.53. The lowest was 4.17. And the median was 13.13.
ASTH's Days Sales Outstanding is ranked better than 60.15% of 655
companies
in the Healthcare Providers & Services industry
Industry Median: 47.32
vs ASTH: 37.53
Astrana Health's Days Sales Outstanding
increased
from Mar. 2025 (38.03) to Mar. 2026 (39.80).
Astrana Health (NAS:ASTH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Astrana Health Days Sales Outstanding Related Terms
Astrana Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Astrana Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASTH vs SNDA, SGRY, AVAH: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Astrana Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Astrana Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astrana Health (ASTH) has a Days Sales Outstanding of 39.80 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Astrana Health and its competitors. This is 203% above median its historical median of 13.13. Over the past decade, Astrana Health's Days Sales Outstanding has ranged from 4.17 to 37.53. According to the industry distribution chart, Astrana Health ranks #261 out of 655 companies in the Healthcare Providers & Services industry, placing it in the top 39.8%.
Is Astrana Health's Days Sales Outstanding too high?
Astrana Health's current Days Sales Outstanding of 39.80 is 203% above median its 10-year median of 13.13. Over the past 10 years, this metric has ranged from a low of 4.17 to a high of 37.53. The Healthcare Providers & Services industry median Days Sales Outstanding is 47.32. Astrana Health's value of 39.80 is 15.9% below this industry median. Based on the distribution chart, Astrana Health ranks #261 out of 655 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Astrana Health has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's Days Sales Outstanding compare to SNDA and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #261 out of 655 companies for Days Sales Outstanding. This puts Astrana Health in the upper half of its industry. The industry median Days Sales Outstanding is 47.32. Astrana Health's value of 39.80 is 15.9% below this benchmark. Historically, Astrana Health's own Days Sales Outstanding has ranged from 4.17 to 37.53 over the past decade. While the company's 10-year median is 13.13 vs. the industry median of 47.32, Astrana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 47.32, based on 655 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current Days Sales Outstanding of 39.80 is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 47.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current Days Sales Outstanding is 39.80, which is 203% above median its own 10-year median of 13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.89, compared to a current price of $35.91 — trading 57.2% below its estimated fair value. The current Days Sales Outstanding is 39.80, which is 203% above median its 10-year median of 13.13 and 15.9% below the Healthcare Providers & Services industry median of 47.32. Astrana Health's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Astrana Health (ASTH), the current Days Sales Outstanding is 39.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $35.91 is trading 57.2% below its estimated GF Value™ of $83.89.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
Days Sales Outstanding: 39.80 (203% above median its 10-year median of 13.13)
GF Value™: $83.89 vs. price of $35.91 (57.2% below fair value)
Industry Position: 15.9% below the Healthcare Providers & Services median (#261 of 655)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
81GF Score
Get the complete analysis for ASTH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
